We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a report released today, Gena Wang from Barclays maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $418.00. The company’s shares closed ...

Mnwabisi Mbangata arrived at Vertex Pharmaceuticals almost two years ago with nearly a decade of experience — including five years at Eli Lilly in various roles — in bringing innovative therapies to ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $409.56, with a -0.62% movement compared to the previous day. This change was narrower than the S&P 500's 1.54% loss on the day.

Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 23 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise ...

Team Kerri Einarson now has a replacement player in Karlee Burgess, Team Chelsea Carey has lost its vice as well as berths in the Scotties Tournament of Hearts and the Canadian Curling Trials ...

Team Kerri Einarson now has a replacement player in Karlee Burgess, Team Chelsea Carey has lost its vice as well as berths in the Scotties Tournament of Hearts and the Canadian curling Trials ...

With Burgess now departed, only two players from last year's squad remain. Team Carey were also qualified for the Olympic Trials after being the highest unqualified team on the CTRS at the end of ...